10-Q: Stoke Therapeutics Reports Q2 2026 Results

Stoke Therapeutics reported a net loss of $61.6 million for Q2 2026, with revenue down significantly year-over-year, while advancing its zorevunersen and STK-002 programs.

Summary

• Stoke Therapeutics reported a net loss of $61.6 million for the three months ended June 30, 2026, compared to a net loss of $23.5 million for the same period in 2025.
• Revenue for the three months ended June 30, 2026, was $9.3 million, a decrease from $13.8 million in the prior year period.
• Research and development expenses increased to $49.5 million from $25.9 million in the prior year period.
• Sales, general, and administrative expenses increased to $25.3 million from $15.3 million in the prior year period.
• The company has $354.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations through early 2028.
• Enrollment for the Phase 3 EMPEROR study of zorevunersen was completed in June 2026, with a data readout anticipated in Q3 2027.
• The OSPREY Phase 1 study for STK-002 has completed dosing for the first cohort, with results anticipated in H1 2027.
• Thomas McCauley was appointed Chief Scientific Officer on July 13, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, increased R&D expenses, and a substantial decrease in revenue compared to the prior year period, despite progress in clinical trials.

Positives

• Enrollment for the Phase 3 EMPEROR study of zorevunersen was completed in June 2026.
• The company expects to have sufficient funding through to potential U.S. commercialization of zorevunersen in early 2028.
• The OSPREY Phase 1 study for STK-002 has completed dosing for the first cohort with no serious safety events observed.
• Zorevunersen has shown substantial and durable reductions in major motor seizure frequency in earlier studies.
• STK-002 in an NHP model of ADOA showed protection and potential improvement in eye health.
• Thomas McCauley was appointed Chief Scientific Officer, responsible for leading scientific strategy.

Negatives

• Net loss for the three months ended June 30, 2026, was $61.6 million, an increase from $23.5 million in the prior year period.
• Revenue for the three months ended June 30, 2026, decreased to $9.3 million from $13.8 million in the prior year period.
• Research and development expenses increased significantly to $49.5 million from $25.9 million in the prior year period.
• Sales, general, and administrative expenses increased to $25.3 million from $15.3 million in the prior year period.
• The company has an accumulated deficit of $609.3 million as of June 30, 2026.
• The company expects to continue incurring net losses for the foreseeable future.

Risks

• Failure to develop, obtain regulatory approval for, and commercialize zorevunersen, STK-002, or future product candidates, or significant delays in doing so, could materially harm the business.
• Success in early preclinical studies or clinical trials may not be indicative of results obtained in later stages.
• The company may not be able to obtain regulatory approval or may receive approval for a narrower indication than sought.
• Difficulty in identifying patients with rare diseases like Dravet syndrome and ADOA could lead to enrollment delays or slower commercial revenue growth.
• Clinical trials may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• The company may not be successful in expanding its pipeline of product candidates.
• The commercial success of product candidates depends on market acceptance by providers, patients, payors, and the medical community.
• Failure to obtain or maintain adequate coverage and reimbursement for product candidates could limit marketability and revenue.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future and anticipates an increase in research and development and sales, general, and administrative expenses. The company believes its current cash, cash equivalents, and marketable securities, along with proceeds from recent ATM sales, will fund operations through to potential U.S. commercialization of zorevunersen in early 2028. However, the company may be unable to raise additional funds on favorable terms or at all, which could negatively impact its ability to pursue business plans.

Management Comments

• The company will continue its educational efforts at major neurology and epilepsy congresses during the second half of 2026.
• Analyses of data from the ongoing OLEs will support efforts to increase clinician understanding of zorevunersen while the Phase 3 EMPEROR study advances toward completion and the Company prepares for a potential U.S. approval and launch.
• The Company will also continue discussions with the FDA to update the Agency on its long-term data for zorevunersen.
• In February 2026, we dosed the first patient with STK-002 in the OSPREY Phase 1 study for the treatment of ADOA.
• As of August 2026, all eight planned clinical trial sites are active in the United Kingdom, Germany, Austria, Italy and Denmark, and dosing of the first cohort of patients (n=3) is complete with no serious safety events observed to date.
• In this new role, Dr. McCauley will be responsible for leading Stokes scientific strategy and leveraging the Companys proprietary RNA medicines platform to expand and advance its pipeline of potential medicines for severe genetic diseases.

Industry Context

StockSavvy.ai notes that Stoke Therapeutics operates in the competitive biotechnology sector, focusing on RNA-based medicines for severe genetic diseases. The company's progress with zorevunersen for Dravet syndrome and STK-002 for ADOA aligns with industry trends towards targeted genetic therapies. However, the significant increase in R&D spending and the year-over-year revenue decline highlight the high-risk, high-reward nature of drug development in this space.

Management Changes

Legal Proceedings

• The company is not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on its business.

Stakeholder Impact

• Shareholders may experience volatility in stock price due to financial performance and clinical trial outcomes.
• Employees' stock-based compensation expense is a significant operating cost.
• Patients with Dravet syndrome and ADOA are potential beneficiaries of the company's drug development programs.
• Collaborators like Biogen and Acadia have significant roles in the development and commercialization of product candidates.

Next Steps

• Continue educational efforts at major neurology and epilepsy congresses.
• Support efforts to increase clinician understanding of zorevunersen with OLE data.
• Advance the Phase 3 EMPEROR study toward completion.
• Prepare for potential U.S. approval and launch of zorevunersen.
• Continue discussions with the FDA regarding long-term data for zorevunersen.
• Dosing in the third and fourth dose cohorts for STK-002 is expected to follow, with a readout of safety and efficacy results anticipated in H1 2027.
• Participate in a pre-NDA meeting with the FDA in H2 2026 for zorevunersen.

Key Dates

Recommendation

While Stoke Therapeutics is making progress in its clinical programs for zorevunersen and STK-002, the significant increase in operating expenses, substantial year-over-year revenue decline, and continued net losses warrant a cautious approach. The company's cash runway extends to early 2028, but future financing needs and the inherent risks of drug development, including regulatory approvals and market acceptance, suggest a 'hold' rating until more definitive clinical data and a clearer path to commercialization emerge.

Keywords

zorevunersen, Dravet syndrome, STK-002, ADOA, RNA-based medicines, clinical trials, biotechnology, drug development